Tazobactam
| Evidence Level: L1 | Predicted Indications: 10 |
Table of Contents
Tazobactam: From Beta-Lactamase Inhibitor Combination Therapy to Pneumonia
One-Sentence Summary
Tazobactam is a beta-lactamase inhibitor that is never used as a standalone agent; it is always paired with a partner beta-lactam antibiotic (e.g., piperacillin, ceftolozane) to extend antibacterial coverage against beta-lactamase-producing pathogens. The TxGNN model predicts it may be effective for Pneumonia, with 50 clinical trials and 20 publications currently supporting this direction — much of it already reflecting established clinical use of tazobactam-containing combination products in hospital-acquired and ventilator-associated pneumonia.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not on file. Tazobactam has no standalone indication of its own, and no EU license records or original-indication text are currently available (Blocking data gap — see below) |
| Predicted New Indication | Pneumonia |
| TxGNN Prediction Score | 99.46% |
| Evidence Level | L1 |
| EU Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the Evidence Pack (Blocking/High-severity data gaps). Based on generally known pharmacology, Tazobactam is a beta-lactamase inhibitor that is always administered as part of a fixed-dose combination (most commonly with piperacillin, or with ceftolozane). It works by irreversibly inhibiting bacterial beta-lactamase enzymes, thereby protecting the partner beta-lactam antibiotic from enzymatic degradation and restoring/extending its activity against beta-lactamase-producing Gram-negative pathogens.
Because Tazobactam has no indication of its own, the “original indication” in this evaluation is best understood as the established use of its combination products (piperacillin/tazobactam, ceftolozane/tazobactam) for serious bacterial infections. Notably, the clinical trial evidence collected for this predicted indication shows that these same tazobactam combinations are already routinely used — often as the active comparator — in large, completed Phase 3 trials for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP). This suggests the TxGNN prediction is capturing a mechanistic relationship that is already substantially supported in real-world clinical practice, rather than an entirely novel repurposing hypothesis.
Mechanistically, this is coherent: pneumonia caused by beta-lactamase-producing Gram-negative organisms (e.g., ESBL-producing Enterobacterales, Pseudomonas aeruginosa) is a plausible and well-precedented target for tazobactam-containing regimens, consistent with the drug’s core mechanism of action.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02493764 | Phase 3 | Completed | 537 | Imipenem/cilastatin/relebactam vs piperacillin/tazobactam in HABP/VABP; non-inferiority on 28-day mortality |
| NCT03583333 | Phase 3 | Completed | 274 | Multinational confirmatory RCT of imipenem/cilastatin/relebactam vs piperacillin/tazobactam in HABP/VABP |
| NCT02070757 | Phase 3 | Completed | 726 | Ceftolozane/tazobactam vs meropenem in ventilated nosocomial pneumonia; non-inferiority on Day-28 mortality |
| NCT00253955 | Phase 3 | Completed | 460 | Levofloxacin vs piperacillin/tazobactam in mild-to-moderate hospital-acquired pneumonia |
| NCT03006679 | Phase 3 | Withdrawn | 0 | Meropenem-vaborbactam vs piperacillin/tazobactam in HABP/VABP (TANGO III; withdrawn before enrollment) |
| NCT01853982 | Phase 3 | Terminated | 4 | Ceftolozane/tazobactam vs piperacillin/tazobactam in ventilator-associated pneumonia (terminated early) |
| NCT03409679 | Phase 3 | Terminated | 41 | Murepavadin + anti-pseudomonal antibiotic vs two anti-pseudomonal antibiotics in VABP due to P. aeruginosa |
| NCT02735707 | Phase 3 | Recruiting | 20,000 | REMAP-CAP adaptive platform trial evaluating multiple interventions for community-acquired pneumonia |
| NCT06294600 | Phase 3 | Recruiting | 330 | Biomarker-guided adjunctive clarithromycin to prevent sepsis progression in community-acquired pneumonia (REACT) |
| NCT01796717 | Phase 2/3 | Unknown | 50 | Optimizing piperacillin/tazobactam dosing (prolonged vs intermittent infusion) for nosocomial pneumonia |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 30208454 | 2018 | RCT | JAMA | Piperacillin-tazobactam vs meropenem for ceftriaxone-resistant E. coli/K. pneumoniae bloodstream infection (MERINO trial) |
| 32785589 | 2021 | RCT | Clin Infect Dis | RESTORE-IMI 2: imipenem/cilastatin/relebactam non-inferior to piperacillin/tazobactam in HABP/VABP |
| 31563344 | 2019 | RCT | Lancet Infect Dis | ASPECT-NP: ceftolozane-tazobactam non-inferior to meropenem for Gram-negative nosocomial pneumonia |
| 39674398 | 2025 | RCT | Int J Infect Dis | Phase 3 non-inferiority trial of imipenem/cilastatin/relebactam vs piperacillin/tazobactam in HABP/VABP |
| 38971203 | 2024 | Systematic Review | Int J Antimicrob Agents | PK/PD review of novel beta-lactam/beta-lactamase inhibitor combinations for pneumonia caused by carbapenem-resistant Gram-negative bacteria |
| 38823453 | 2024 | Network Meta-Analysis | Clin Microbiol Infect | Empiric antibiotic regimens in non-ventilator hospital-acquired pneumonia |
| 32662691 | 2020 | Review | Expert Rev Anti Infect Ther | Ceftolozane/tazobactam for treatment of hospital-acquired pneumonia |
| 35488823 | 2022 | Review | Rev Esp Quimioter | Ceftolozane-tazobactam in nosocomial pneumonia |
| 10353303 | 1999 | Review | Drugs | Updated review of piperacillin/tazobactam in bacterial infections, including lower respiratory tract infection |
| 34598422 | 2021 | Review | Rev Esp Quimioter | When, how, and why to use ceftolozane-tazobactam |
Safety Considerations
Please refer to the SmPC for safety information. No key warnings, contraindications, or drug–drug interaction data are currently available in this Evidence Pack (DDI query status: not found, 0 interactions recorded).
Conclusion and Next Steps
Decision: Hold
Rationale:
- Clinical evidence is strong (Evidence Level L1): multiple completed Phase 3 RCTs directly involve tazobactam-containing combinations (piperacillin/tazobactam, ceftolozane/tazobactam) as either the investigational or active-comparator arm in hospital-acquired/ventilator-associated pneumonia, and this is reinforced by RCT-level literature (JAMA, Lancet Infectious Diseases, Clinical Infectious Diseases).
- However, a Blocking data gap exists: TFDA label warnings/contraindications are missing, and the pack explicitly notes this prevents entry into the S1 safety pre-assessment stage. Given Tazobactam is only ever used in fixed combinations, a proper safety review must be anchored to the specific combination product’s label, which is not yet available.
- Mechanism-of-action data is also missing (High severity), limiting the ability to fully document the mechanistic rationale beyond general class-level pharmacology.
To proceed, the following is needed:
- TFDA (or equivalent regulatory) label warnings and contraindications for the relevant tazobactam-containing combination product(s), to unblock safety pre-assessment (S1)
- Confirmed mechanism of action (MOA) data via DrugBank API query
- Clarification of which specific combination product (piperacillin/tazobactam vs ceftolozane/tazobactam vs other) is the intended candidate, since regulatory and safety profiles differ between them
- EU marketing authorization and license data, currently absent (0 licenses on file)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.